Skip to main content
$0.61 $0.00 (-0.4%)

04:00 PM EDT on 09/29/23

Invitae (NYSE:NVTA)

CAPS Rating: 4 out of 5

Current Price $0.61 Mkt Cap $161.6M
Open $0.63 P/E Ratio -0.19
Prev. Close $0.61 Div. (Yield) $0.00 (0.0%)
Daily Range $0.60 - $0.63 Volume 8,473,701
52-Wk Range $0.60 - $3.78 Avg. Daily Vol. 10,099,385

Caps

How do you think NYSE:NVTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

414 Outperform
10 Underperform
 

All-Star Players

32 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:NVTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

draber (< 20)
Submitted October 12, 2021

I purchased this stock because I feel that it is the BEST opportunity in Biotechnology for the expansion of diagnostic testing for inherited diseases, cancers etc to the general public and medical professionals PLUS it is currently at a bargain price… More

eddehhh (< 20)
Submitted July 15, 2020

Targeted tests might do well in short term but it is bound to disappear as the industry moves toward whole sequence diagnostics.

NYSE:NVTA Summary

Fools bullish on NYSE:NVTA are also bullish on:

Fools bearish on NYSE:NVTA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NVTA.

Recs

0
Member Avatar thecolonel79 (68.29) Submitted: 8/26/2022 12:00:26 PM : Outperform Start Price: $24.35 NYSE:NVTA Score: -124.65

Finally getting serious about making money.

Recs

0
Member Avatar leaderoftheback (39.80) Submitted: 11/27/2021 9:43:50 AM : Outperform Start Price: $10.95 NYSE:NVTA Score: -91.22

November '21; current trade at $18 and trending down. Uncertain of long-term prospects but most risk should be out at $11 start, as that is just slightly above old (more sensible) support levels, though sales have grown significantly since.

Recs

1
Member Avatar draber (< 20) Submitted: 10/12/2021 11:01:37 AM : Outperform Start Price: $26.34 NYSE:NVTA Score: -95.99

I purchased this stock because I feel that it is the BEST opportunity in Biotechnology for the expansion of diagnostic testing for inherited diseases, cancers etc to the general public and medical professionals PLUS it is currently at a bargain price @ $26.49

Leaderboard

Find the members with the highest scoring picks in NVTA.

Score Leader

FinanceGuy58

FinanceGuy58 (58.27) Score: +476.70

The Score Leader is the player with the highest score across all their picks in NVTA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
chipotlepickle 94.65 4/20/2016 Underperform 1Y $10.77 -94.38% +103.61% +197.99 0 Comment
LazyHarlequin 93.14 5/8/2019 Underperform 5Y $20.03 -96.98% +48.04% +145.02 1 Comment
Capitalism 74.89 11/18/2019 Underperform 5Y $18.26 -96.69% +36.94% +133.63 1 Comment
jdgrn01 < 20 2/26/2020 Underperform 3Y $20.70 -97.08% +35.84% +132.92 1 Comment
Philhi 61.21 12/20/2021 Underperform 5Y $16.75 -96.39% -5.46% +90.93 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. chammond55 85.08 4/27/2022 Underperform 5Y $5.09 -88.11% +2.45% +90.56 0 Comment
TMFdjagielski 40.77 9/23/2022 Underperform 1Y $2.43 -75.09% +15.35% +90.44 0 Comment
baf72167 < 20 12/21/2021 Underperform 5Y $16.61 -96.36% -6.75% +89.61 0 Comment
markkinney1988 21.49 8/15/2022 Underperform 1Y $4.47 -86.46% +0.64% +87.10 0 Comment
AllFunkedUp < 20 12/30/2021 Underperform 3Y $15.90 -96.19% -10.54% +85.65 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVTA.